IJDVL Home  
 

CASE REPORT
[View FULLTEXT] [Download PDF]  
Year : 2019  |  Volume : 85  |  Issue : 1  |  Page : 56-59

Successful treatment of metastatic extramammary Paget's disease with pemetrexed monotherapy systemically and 5-fluorouracil topically

Kexu Chen1, Hanlin Liang3, Jiewen Peng3, Yanfang Zheng2 
1 Department of Oncology, Southern Medical University, Guangzhou; Department of Chemotherapy, Zhongshan People's Hospital, Zhongshan, Guangdong Province, People's Republic of China
2 Department of Oncology, Southern Medical University, Guangzhou, People's Republic of China

Correspondence Address:
Dr. Hanlin Liang
Department of Chemotherapy, Zhongshan People's Hospital, Zhongshan, Guangdong Province
People's Republic of China

Advanced extramammary Paget's disease does not have a standardized treatment guideline as its incidence is low and has been rarely reported in literature. Here we describe a case of metastatic extramammary Paget's disease successfully treated with topical 5-fluorouracil (5-FU) and systemic pemetrexed. The therapy was safe without any appreciable adverse effects like diarrhea, rash, neutropenia or fatigue; maintaining remission for more than 6 months. Thus, we propose 5-FU and pemetrexed as the first-line therapy for advanced extramammary Paget's disease, especially for aged patients with unresectable skin lesions.


How to cite this article:
Chen K, Liang H, Peng J, Zheng Y. Successful treatment of metastatic extramammary Paget's disease with pemetrexed monotherapy systemically and 5-fluorouracil topically.Indian J Dermatol Venereol Leprol 2019;85:56-59


How to cite this URL:
Chen K, Liang H, Peng J, Zheng Y. Successful treatment of metastatic extramammary Paget's disease with pemetrexed monotherapy systemically and 5-fluorouracil topically. Indian J Dermatol Venereol Leprol [serial online] 2019 [cited 2020 Feb 29 ];85:56-59
Available from: http://www.ijdvl.com/article.asp?issn=0378-6323;year=2019;volume=85;issue=1;spage=56;epage=59;aulast=Chen;type=0


 

Saturday, February 29, 2020
 Site Map | Home | Contact Us | Feedback | Copyright and disclaimer